Semaglutide Research Overview

This guide provides a comprehensive evaluation of one research peptide classified under the Metabolic / GLP-1 Agonist category. Each compound is assessed based on its supporting evidence, mechanistic properties, safety considerations, and current status in clinical research. The analysis draws from published studies to contextualize the peptide's potential applications in metabolic health research.

Evidence: A | Status: FDA-approved (Ozempic for T2D, Wegovy for obesity)

Semaglutide is a GLP-1 receptor agonist with a molecular weight of approximately 4113.6 g/mol and a molecular formula of C187H291N45O59. It shares 94% sequence homology with endogenous human GLP-1, a modification that enhances its resistance to enzymatic degradation and prolongs its half-life. This structural similarity allows it to activate GLP-1 receptors effectively, mimicking the incretin hormone's effects on glucose-dependent insulin secretion and appetite regulation.

Use cases: Weight Management, Metabolic Health, Cardiovascular

In clinical trials, semaglutide has demonstrated significant reductions in body weight and improvements in glycemic control among individuals with type 2 diabetes. Research also indicates potential cardiovascular benefits, including reduced risk of major adverse cardiovascular events in high-risk populations. Preclinical studies further explore its effects on metabolic pathways, such as delayed gastric emptying and enhanced satiety signaling, which contribute to its therapeutic profile.